We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SUGP:NASDAQSU Group Holdings Limited Analysis

Data as of 2026-05-03 - not real-time

$4.33

Latest Price

8/10Risk

Risk Level: High

Executive Summary

The stock is trading at $4.33, well below its 200‑day SMA of $6.10, indicating a significant discount to its long‑term trend. However, the 20‑day SMA ($4.70) sits above the current price, confirming short‑term weakness. The 14‑day RSI at 32.6 points to oversold conditions, suggesting potential for a rebound. MACD remains in bearish territory, with the line (-0.19) below the signal (-0.16) and a negative histogram, reinforcing downside momentum. Volume is increasing, yet price remains trapped between support at $4.17 and resistance at $5.11, limiting upside. The stock’s beta of 2.07 and 30‑day volatility of 44.5% signal extreme price swings, amplifying risk.
Fundamentally, the company reports negative operating margin (-17.8%) and a net loss per share of -$1.71, with a trailing EPS of -1.71, highlighting earnings weakness. Yet its price‑to‑book ratio of 0.58 and price‑to‑sales of 0.05 are far below industry averages, implying a deep value discount. The balance sheet shows modest cash of $25.3 M against debt of $5.5 M, resulting in a high debt‑to‑equity of 6.4, which could strain liquidity. Free cash flow is negative ($‑13.3 M) and operating cash flow also negative, raising concerns about cash generation. The maximum historical drawdown of -73.9% and a market cap of only $10.2 M underscore the company’s fragility. Coupled with an “Extreme Greed” market sentiment, the technical and fundamental picture points to a high‑risk, value‑oriented play.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 8/10

Key Factors

  • Bearish MACD histogram
  • RSI below 40 indicating oversold but momentum still negative
  • Price below short‑term SMA and approaching support level

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Deep valuation discount (low P/B and P/S)
  • Continued negative earnings and cash flow
  • High beta and volatility may delay recovery

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Potential upside if turnaround improves margins
  • Strong asset base relative to market cap
  • Persistent regulatory and liquidity challenges

Key Metrics & Analysis

Financial Health

Revenue Growth-6.50%
Profit Margin-9.61%
ROE-20.11%
ROA-7.94%
Debt/Equity6.40
P/B Ratio0.6
Op. Cash Flow$-15456974
Free Cash Flow$-13327510
Industry P/E31.2

Technical Analysis

TrendBearish
RSI32.6
Support$4.17
Resistance$5.11
MA 20$4.70
MA 50$4.96
MA 200$6.10
MACDBearish
VolumeIncreasing
Fear & Greed Index91.09

Valuation

GradeUndervalued
TypeValue

Risk Assessment

Beta2.07
Volatility44.54%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.